打开APP

阿斯利康与Advaxis在癌症免疫疗法建立合作关系

  1. advaxis
  2. 癌症免疫疗法
  3. 阿斯利康

来源:生物谷 2014-07-23 13:52

阿斯利康公司最近宣布公司已经与普林斯顿的生物技术公司Advaxis公司达成合作协议共同开发癌症免疫疗法。

2014年7月23日讯 /生物谷BIOON/ --阿斯利康公司最近宣布公司已经与普林斯顿的生物技术公司Advaxis公司达成合作协议共同开发癌症免疫疗法。阿斯利康公司希望能够将公司现在正在开发的MEDI4736药物与Advaxis开发的HPV癌症疫苗相结合。Advaxis 公司最近刚刚公布了其ADXS-HPV疫苗中期研究的存活率数据,参加研究的109名女性有22%的生存期超过18个月。阿斯利康公司希望能够将ADXS-HPV作为自己癌症免疫疗法的有力补充。 Advaxis CEO Daniel J. O'Connor 表示这也是PD-L1疗法被应用到新尺度的治疗中。双方的合作消息一经公布,Advaxis的股价也应声上扬。


近年来默沙东、辉瑞、罗氏和施贵宝等生物医药巨头纷纷在癌症免疫疗法研究领域中投入巨大人力物力,希望能够带来癌症治疗的一场新革命。目前这些医药巨头都开发有自己的抗PD-L1药物,如默沙东的pembrolizumab (MK-34-75)等。同时各大制药商还在这一领域合纵连横,建立了广泛的合作协议。例如施贵宝和罗氏就在这一领域达成了合作协议。(生物谷Bioon.com)


详细英文报道:
AstraZeneca ($AZN) has partnered up with Princeton, NJ-based Advaxis on a program that pairs the pharma giant's closely watched immuno-oncology drug MEDI4736 with the biotech's therapeutic cancer vaccine for HPV-related cancers.

Advaxis has been touting some midstage survival data for ADXS-HPV this year, with 22% of 109 women with recurrent cervical cancer making it past the 18-month milestone in a single-arm study. The biotech uses benign bacteria as a delivery vehicle, looking to kick-start an immune response to the cancer. Now the biotech will fund a combination study to see how patients respond to an immuno-oncology duo, with AstraZeneca's candidate taking down the defense system employed by cancer cells while ADXS-HPV marshals an attack.

Shares of Advaxis ($ADXS) surged 8% Tuesday morning.

Like Merck ($MRK), Bristol-Myers Squibb ($BMY) and Roche ($RHHBY)--which are leading the IO field with AstraZeneca--the Big Pharma company knows that the second wave of cancer therapies will be in combination assaults like this one. AstraZeneca already signed on to pair the anti-PD-L1 drug MEDI4736. being developed by its biologics subsidiary MedImmune, with Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360. Merck has executed a long series of pacts while Bristol-Myers has been busy partnering and Roche links up with a string of in-house therapies.

Therapeutic cancer vaccines are a likely partner for the top IO companies. They employ complementary approaches to treating cancer and the vaccine crowd has been dogged by often lackluster performance in the clinic. The immunotherapeutic vaccines could use a boost and pharma needs all the biotech partners it can find to develop new products with some of the most impressive technology to come along in years. The attention AstraZeneca has won for MEDI4736 has gone a long way to convincing investors that the company has a big future in cancer drugs, which helped it stave off an unwanted takeover attempt from Pfizer ($PFE).

Merck recently executed a lineup of collaborations for pembrolizumab (MK-34-75), the star immuno-oncology program at the pharma giant which has stirred immense excitement as it barrels toward its first decision from the FDA. In that slate of partnerships Merck included INCB24360. Bristol-Myers, meanwhile, isn't being left out of the frenzied partnering now going on in the field. Celldex says it's pairing its CD27-targeting antibody varlilumab with nivolumab in a Phase I/II study. And Bristol-Myers is paying $5 million for the privilege, with the two companies splitting the trial costs.

"This is the first time a PD-L1 checkpoint inhibitor will be used with a new class of immunotherapies," says Advaxis CEO Daniel J. O'Connor in a statement. "As multiple companies vie for a competitive advantage in the future PD-L1 market, the ability of our immunotherapy platform to attack multiple tumour targets makes it an attractive combination therapy."

 


 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->